CN101505794B - 穿过上皮和/或内皮层的scFV抗体 - Google Patents

穿过上皮和/或内皮层的scFV抗体 Download PDF

Info

Publication number
CN101505794B
CN101505794B CN2007800314717A CN200780031471A CN101505794B CN 101505794 B CN101505794 B CN 101505794B CN 2007800314717 A CN2007800314717 A CN 2007800314717A CN 200780031471 A CN200780031471 A CN 200780031471A CN 101505794 B CN101505794 B CN 101505794B
Authority
CN
China
Prior art keywords
antigen
ser
gly
pharmaceutical composition
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2007800314717A
Other languages
English (en)
Chinese (zh)
Other versions
CN101505794A (zh
Inventor
A·奥弗德毛尔
A·巴伯利斯
D·厄里什
P·李奇特兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Esbatech An Alcon Biomedical Research Unit LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esbatech An Alcon Biomedical Research Unit LLC filed Critical Esbatech An Alcon Biomedical Research Unit LLC
Priority to CN201310159387.0A priority Critical patent/CN103251947B/zh
Publication of CN101505794A publication Critical patent/CN101505794A/zh
Application granted granted Critical
Publication of CN101505794B publication Critical patent/CN101505794B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN2007800314717A 2006-07-10 2007-07-10 穿过上皮和/或内皮层的scFV抗体 Active CN101505794B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201310159387.0A CN103251947B (zh) 2006-07-10 2007-07-10 穿过上皮和/或内皮层的scFV抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81937806P 2006-07-10 2006-07-10
US60/819,378 2006-07-10
US89990707P 2007-02-06 2007-02-06
US60/899,907 2007-02-06
PCT/CH2007/000334 WO2008006235A2 (fr) 2006-07-10 2007-07-10 ANTICORPS scFv TRAVERSANT DES COUCHES ENDOTHÉLIALES ET/OU ÉPITHÉLIALES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310159387.0A Division CN103251947B (zh) 2006-07-10 2007-07-10 穿过上皮和/或内皮层的scFV抗体

Publications (2)

Publication Number Publication Date
CN101505794A CN101505794A (zh) 2009-08-12
CN101505794B true CN101505794B (zh) 2013-09-04

Family

ID=38792084

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201310159387.0A Active CN103251947B (zh) 2006-07-10 2007-07-10 穿过上皮和/或内皮层的scFV抗体
CN2007800314717A Active CN101505794B (zh) 2006-07-10 2007-07-10 穿过上皮和/或内皮层的scFV抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201310159387.0A Active CN103251947B (zh) 2006-07-10 2007-07-10 穿过上皮和/或内皮层的scFV抗体

Country Status (16)

Country Link
US (2) US8936785B2 (fr)
EP (2) EP3093026B1 (fr)
JP (6) JP2009542232A (fr)
CN (2) CN103251947B (fr)
AU (1) AU2007272224B2 (fr)
CA (1) CA2658241C (fr)
DK (1) DK2046382T3 (fr)
ES (2) ES2820837T3 (fr)
HU (1) HUE032654T2 (fr)
LT (1) LT2046382T (fr)
NZ (2) NZ700275A (fr)
PL (1) PL2046382T3 (fr)
PT (1) PT2046382T (fr)
RU (3) RU2438708C2 (fr)
SI (1) SI2046382T1 (fr)
WO (1) WO2008006235A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010102078A1 (fr) * 2009-03-04 2010-09-10 Allergan, Inc. Solution ophtalmique améliorée à base de bimatoprost
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
EP3093026B1 (fr) 2006-07-10 2020-07-01 ESBATech, an Alcon Biomedical Research Unit LLC Anticorps scfv traversant des couches endothéliales et/ou epithéliales
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
CN106366192B (zh) 2007-06-25 2020-03-27 艾斯巴技术-诺华有限责任公司 修饰抗体的方法和具有改善的功能性质的修饰抗体
SI2164961T1 (sl) * 2007-06-25 2015-05-29 Esbatech, An Alcon Biomedical Research Unit Llc InĹľeniring na osnovi zaporedij in optimizacija mono-veriĹľnih protiteles
EP2197914A1 (fr) 2007-09-13 2010-06-23 Delenex Therapeutics AG Anticorps humanisés contre le peptide bêta-amyloïde
WO2009097704A1 (fr) * 2008-02-05 2009-08-13 Esbatech Ag Polypeptides se liant à l'antigène pour lutter contre la dégénérescence du cartilage
JP2009294202A (ja) * 2008-05-09 2009-12-17 Pola Chem Ind Inc タイトジャンクションの物質輸送への関与の鑑別法
LT3241843T (lt) 2008-06-25 2021-09-27 Novartis Ag Imuninių rišiklių tirpumo optimizavimas
CA2728004C (fr) 2008-06-25 2022-05-24 Esbatech, An Alcon Biomedical Research Unit Llc Humanisation d'anticorps de lapins au moyen d'une infrastructure d'anticorps universelle
CN102076716A (zh) 2008-06-25 2011-05-25 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 抑制TNFα的稳定和可溶的抗体
LT3216803T (lt) 2008-06-25 2020-06-10 Novartis Ag Stabilūs ir tirpūs antikūnai, slopinantys vegf
SI2307458T1 (en) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanization of rabbit antibodies using a universal antibody framework
EP2304033B1 (fr) 2008-06-30 2016-09-07 ESBATech, an Alcon Biomedical Research Unit LLC Polypeptides fonctionnalisés
WO2010003268A2 (fr) 2008-07-10 2010-01-14 Esbatech, An Alcon Biomedical Research Unit Llc Procédés et compositions favorisant l'administration de macromolécules
EP3181583A1 (fr) 2009-02-24 2017-06-21 ESBATech, an Alcon Biomedical Research Unit LLC Procédés pour identifier des agents de liaison immunologique d'antigènes
US9079953B2 (en) * 2009-06-17 2015-07-14 Abbvie Biotherapeutics Inc. Anti-VEGF antibodies and their uses
US8399625B1 (en) 2009-06-25 2013-03-19 ESBATech, an Alcon Biomedical Research Unit, LLC Acceptor framework for CDR grafting
US9522153B2 (en) 2009-12-22 2016-12-20 Allergan, Inc. Compositions and methods for lowering intraocular pressure
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
US20140154255A1 (en) 2012-11-30 2014-06-05 Abbvie Biotherapeutics Inc. Anti-vegf antibodies and their uses
US11079613B2 (en) * 2013-03-05 2021-08-03 EyeYon Medical Ltd. Contact lens drug depot
WO2015086830A1 (fr) * 2013-12-13 2015-06-18 Delenex Therapeutics Ag Polypeptides pénétrant dans la peau
JP6748061B2 (ja) * 2014-07-09 2020-08-26 ルピン・リミテッド 二重シストロン細菌発現システム
KR102706856B1 (ko) 2015-07-21 2024-09-19 아베드로 인코퍼레이티드 광증감제로 눈을 치료하기 위한 시스템 및 방법
HUE052993T2 (hu) * 2015-08-17 2021-06-28 Lupin Ltd Fejlesztett újrahajtogatási eljárás antitest fragmensekhez
US11269987B2 (en) 2019-09-09 2022-03-08 International Business Machines Corporation Security credentials management for client applications
WO2024058730A1 (fr) 2022-09-15 2024-03-21 Vsy Biyoteknoloji Ve Ilac Sanayi Anonim Sirketi Fragments de scfv anti-angiogéniques stables et puissants et leurs utilisations comme antagonistes de vegf

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2434A (en) * 1842-01-24 Improvement in the mode of propelling boats by means of endless chains of paddles
US2433A (en) * 1842-01-24 Improvement in the construction of apparatus for condensing air to be
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4093709A (en) * 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4304767A (en) * 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4946931A (en) 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5968543A (en) * 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
JP5483789B2 (ja) * 1999-01-05 2014-05-07 ザ フリンダーズ ユニバーシティ オブ サウス オーストラリア 眼障害を治療及び診断するための新規な薬物及び方法
AU6526100A (en) * 1999-08-06 2001-03-05 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
DK1242457T3 (da) * 1999-12-28 2004-12-20 Esbatech Ag Intracellulære antistoffer [intracellulære antistoffer] med defineret struktur, der er stabil i et reducerende miljö, og anvendelse deraf
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
US6524606B1 (en) * 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US20030165545A1 (en) * 2002-01-30 2003-09-04 Allergan, Inc. Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same
CA2379661A1 (fr) 2002-03-28 2003-09-28 Kursad Turksen Systeme d'administration paracellulaire de medicament
CN105175535A (zh) 2002-05-22 2015-12-23 艾斯巴技术-诺华有限责任公司 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
WO2005009464A1 (fr) * 2003-07-25 2005-02-03 Lopez De Silanes Juan Administration de fragments d'anticorps f(ab')2 anti-cytokiniques
US20050266005A1 (en) 2004-02-27 2005-12-01 Heavner George A Methods and compositions for treating IL-3 related pathologies
US20060062758A1 (en) 2004-09-21 2006-03-23 Nastech Pharmaceutical Comapny Inc. Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds
US20070160606A1 (en) 2004-09-30 2007-07-12 Heavner George A Treating renal cell carcinoma with an anti-TNF human antibody or fragment
US7431927B2 (en) * 2005-03-24 2008-10-07 Epitomics, Inc. TNFα-neutralizing antibodies
US20080044420A1 (en) 2005-05-11 2008-02-21 Heavner George A Anti-IL-13 antibodies, compositions, methods and uses
EP3260465A1 (fr) * 2005-06-07 2017-12-27 ESBATech, an Alcon Biomedical Research Unit LLC Anticorps stables et solubles inhibant le tnf-alpha
US20070141092A1 (en) * 2005-12-21 2007-06-21 Erning Xia Biguanide composition and method of treatment and prevention of viral infections
US20070178103A1 (en) * 2006-01-30 2007-08-02 Fey Georg H CD19-specific immunotoxin and treatment method
EP3093026B1 (fr) 2006-07-10 2020-07-01 ESBATech, an Alcon Biomedical Research Unit LLC Anticorps scfv traversant des couches endothéliales et/ou epithéliales

Also Published As

Publication number Publication date
WO2008006235A3 (fr) 2008-02-28
PT2046382T (pt) 2016-11-23
RU2011126239A (ru) 2012-12-27
NZ700275A (en) 2016-03-31
CN103251947B (zh) 2017-11-21
HUE032654T2 (en) 2017-10-30
DK2046382T3 (en) 2016-12-12
NZ574308A (en) 2012-06-29
RU2565399C2 (ru) 2015-10-20
JP2017209114A (ja) 2017-11-30
EP3093026A1 (fr) 2016-11-16
US20140234315A1 (en) 2014-08-21
EP2046382B1 (fr) 2016-08-17
US20090311251A1 (en) 2009-12-17
AU2007272224B2 (en) 2013-05-02
RU2015130221A3 (fr) 2019-04-01
PL2046382T3 (pl) 2017-07-31
JP6226824B2 (ja) 2017-11-08
CN103251947A (zh) 2013-08-21
RU2009104318A (ru) 2010-08-20
JP2014169329A (ja) 2014-09-18
CA2658241C (fr) 2018-01-02
ES2820837T3 (es) 2021-04-22
EP3093026B1 (fr) 2020-07-01
AU2007272224A1 (en) 2008-01-17
SI2046382T1 (sl) 2016-12-30
WO2008006235A2 (fr) 2008-01-17
JP6230195B2 (ja) 2017-11-15
LT2046382T (lt) 2016-12-12
RU2438708C2 (ru) 2012-01-10
CA2658241A1 (fr) 2008-01-17
EP2046382A2 (fr) 2009-04-15
JP2014176392A (ja) 2014-09-25
ES2603399T3 (es) 2017-02-27
JP2019089809A (ja) 2019-06-13
JP2009542232A (ja) 2009-12-03
US8936785B2 (en) 2015-01-20
CN101505794A (zh) 2009-08-12
RU2015130221A (ru) 2017-01-27
JP2016041758A (ja) 2016-03-31

Similar Documents

Publication Publication Date Title
CN101505794B (zh) 穿过上皮和/或内皮层的scFV抗体
Carter et al. Next generation antibody drugs: pursuit of the'high-hanging fruit'
RU2670943C2 (ru) Антагонисты ил-6 и их применение
TWI708785B (zh) 具有改善的藥物動力學的抗ｃ５抗體
ES2685607T3 (es) Usos y composiciones para el tratamiento de la hidradenitis supurativa (HS)
CN104968678B (zh) 靶向epo的抗体的组合物和方法
CN104995303A (zh) 利用结合乙酰透明质酸的肽标签的组合物和方法
CN105936648A (zh) Cd28结合为单价的组合物及使用方法
CN106536561A (zh) 抗‑因子d抗体变体及其用途
CN107206081A (zh) 治疗炎性疾病的方法
CN102224169A (zh) 多肽、抗体可变结构域和拮抗剂
EP3990488A1 (fr) Anticorps semaphorine 3a et leurs utilisations
JP2024515066A (ja) 補体因子ｄを標的とする抗体及びその使用
AU2016200367B2 (en) scFv antibodies which pass epithelial and/or endothelial layers
AU2017235901A1 (en) scFv antibodies which pass epithelial and/or endothelial layers
AU2013203533A1 (en) scFv antibodies which pass epithelial and/or endothelial layers
WO2024094076A1 (fr) Protéine de liaison au gipr et son utilisation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: ESBATECH-NOVARTIS COMPANY LLC

Free format text: FORMER NAME: ESBATECH, ESBATECH ALCON BIOMEDICAL RESEARCH UNIT LLC

CP01 Change in the name or title of a patent holder

Address after: Swiss Shi Lilun

Patentee after: Esbatech Alcon Biomed Res Unit

Address before: Swiss Shi Lilun

Patentee before: Esbatech Alcon Biomed Res Unit

EE01 Entry into force of recordation of patent licensing contract

Application publication date: 20090812

Assignee: Delenex Therapeutics AG

Assignor: Esbatech Alcon Biomed Res Unit

Contract record no.: 2014990000590

Denomination of invention: Scfv antibodies which pass epithelial and/or endothelial layers

Granted publication date: 20130904

License type: Common License

Record date: 20140724

LICC Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model
TR01 Transfer of patent right

Effective date of registration: 20220418

Address after: Basel, SUI

Patentee after: NOVARTIS AG

Address before: Swiss Shi Lilun

Patentee before: ESBATECH - A NOVARTIS CO.,LLC

TR01 Transfer of patent right